Developer docs
API playgroundTry for free, no card

Search company profiles

Orion Pharma

Full company profile

uuid0009tgi

Namestring
Orion Pharma
Legal namestring
Orion Corporation
Websiteurl
orionpharma.se
Company typeenum
Public
Founded yearint
1917
Descriptiontext

Orion Pharma is the consumer-facing brand of Orion Corporation, a Finnish pharmaceutical company founded in 1917 by three pharmacists and now publicly listed on Nasdaq Helsinki under ticker ORNBV. Orion Corporation, headquartered in Espoo, Finland, develops, manufactures and markets human and veterinary medicines, active pharmaceutical ingredients, generics and biosimilars, and a Scandinavian-focused portfolio of OTC medical devices and self-care products sold under brands including AcidDuo, Bevita Eye, Melatonin Orion Pharma, Oriptan, Pronaxen, Pyrvin, Revaxör and Stérimar. The company employs more than 3,500 people across 30+ countries and distributes its products in over 100 countries.

Core R&D is concentrated in two therapeutic areas: oncology and pain. The lead pipeline asset is ODM-212, a proprietary TEAD inhibitor in the Phase 1b/2 TEADCO clinical trial evaluating combination regimens in malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Beyond oncology and pain, Orion's prescription portfolio spans respiratory (asthma/COPD, allergic rhinitis), neurology (epilepsy, neuropathic pain), psychiatry (schizophrenia, bipolar disorder), gastroenterology (ulcerative colitis), and urology (prostate cancer). The self-care and veterinary businesses extend the company's reach into consumer pharmacy shelves and animal health respectively.

Orion generates revenue through one-time sales across prescription pharmaceuticals, OTC/self-care products, veterinary medicines, generics/biosimilars, and B2B API supply. Commercial reach is executed via field sales representatives engaging healthcare professionals, distributor networks for global Rx distribution, retail and online pharmacy chains (Apotea, Apoteket.se, Apotek Hjärtat, Kronans Apotek, DOZ Apotek, MEDS) for OTC products in Scandinavia, and the Well by Orion Pharma e-commerce storefront for direct-to-consumer self-care. The company is also a founding member of the Apheris ADMET Network, a federated AI initiative for collaborative drug-discovery model training alongside Lundbeck, Recursion and Servier.

Short descriptiontext

Orion Corporation is a Finnish pharmaceutical company (founded 1917, Nasdaq Helsinki: ORNBV) developing, manufacturing and marketing prescription drugs focused on oncology and pain, generics and biosimilars, OTC self-care products, veterinary medicines, and APIs, serving patients, healthcare professionals and consumers across over 100 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersDanderyd, Sweden
HQ citystring
Danderyd
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, oncology drug development, pain management medicines, OTC self-care products, active pharmaceutical ingredients
Industry8 codes
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAMAIAJ
Animal Health OTC Retail (Parasite Control, Basic Care)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
SECONDARYHLAMAIAD
Compounding Pharmacies (Veterinary)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Prescription Pharmaceuticals
TypeOne Time License
Description

Orion develops, manufactures and markets prescription medicines covering multiple therapy areas including oncology, pain, respiratory (asthma/COPD), neurology (epilepsy, schizophrenia, bipolar disorder), and gastroenterology (ulcerative colitis). Products are distributed through pharmacies and healthcare providers globally.

orionpharma.se
2OTC/Egenvård Products
TypeOne Time License
Description

Self-care/OTC products including AcidDuo (heartburn), Bevita Eye (dry eyes), Melatonin Orion Pharma (jet lag), Oriptan (migraine), Pronaxen (pain), Pyrvin (pinworm), Revaxör (ear wax), and Stérimar (nasal spray). Sold through pharmacies and online pharmacy retailers across Scandinavia.

orionpharma.se
3Veterinary Medicines
TypeOne Time License
Description

Orion develops and manufactures veterinary pharmaceutical products for animal health.

orionpharma.se
4Generic and Biosimilar Drugs
TypeOne Time License
Description

Cost-saving generic and biosimilar pharmaceuticals complementing innovative originator products.

orionpharma.se
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Orion Pharma develops, manufactures, and markets pharmaceutical products for humans and animals, with research and development focused on oncology and pain. The company offers a diversified portfolio including prescription drugs, generic and biosimilar medicines, OTC/self-care products (acid reflux, dry eyes, migraine, pain, jet lag, ear/nasal care), veterinary medicines, and active pharmaceutical ingredients supplied to other pharmaceutical companies. Products are available in over 100 countries globally, with OTC brands distributed through pharmacy chains across Scandinavia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Products available in over 100 countries
+1 more record
Product overview1 text field

Orion Pharma is a Finnish pharmaceutical company operating globally with products in over 100 countries. The company offers a diversified portfolio consisting of prescription medications (with focus on pain and oncology), generic drugs and biosimilars, active pharmaceutical ingredients, veterinary pharmaceuticals, and consumer self-care products. The self-care portfolio includes OTC medical devices and medications sold through pharmacies and online pharmacies across Scandinavia, comprising AcidDuo (heartburn relief), Bevita Eye (dry eye treatment), Melatonin Orion Pharma (jet lag relief), Oriptan (migraine treatment), Pronaxen (pain relief), Pyrvin (pinworm treatment), Revaxör (ear care), and Stérimar (nasal spray with natural seawater), all available under the Orion Pharma brand. The company also operates Well by Orion Pharma as an e-commerce platform for wellness products. Orion's prescription drug development focuses primarily on pain and oncology therapeutic areas.

Product and service13 records
1AcidDuo
CategoryOTC medical device
Description

OTC medical device: chewable tablets that form a protective barrier against stomach acid to relieve heartburn and acid reflux. Sold to consumers through pharmacies across Scandinavia.

2Bevita Eye
CategoryOTC medical device
Description

OTC medical device: eye drops and ointment for dry eye symptoms, containing hyaluronic acid and vitamin A to moisturize and protect the eye surface. CE-marked, sold through pharmacies.

3Melatonin Orion Pharma 3 mg and 5 mg
CategoryOTC medication
Description

OTC medication: melatonin tablets for short-term treatment of jet lag in adults, helping reset the body's internal clock after crossing time zones.

4Oriptan (sumatriptan)
CategoryOTC medication
Description

OTC medication: 50 mg sumatriptan tablets for acute migraine attacks with or without aura. Recept-free (non-prescription) OTC format.

5Pronaxen (naproxen)
CategoryOTC medication
Description

OTC medication: naproxen tablets providing pain relief, fever reduction, and anti-inflammatory action for adults and adolescents from 12 years for mild to moderate acute pain including menstrual cramps, headache, toothache, muscle and joint pain.

6Pyrvin (pyrvinium embonate)
CategoryOTC medication
Description

OTC medication: film-coated tablets for treatment of threadworm (pinworm) in children and adults, administered as a single dose repeated after two weeks.

7Revaxör
CategoryOTC medical device
Description

OTC medical device: earwax-removing spray and drops plus caring oil for earwax and earwax plug removal. CE-marked, sold through pharmacies.

8Stérimar
CategoryOTC medical device
Description

OTC medical device: nasal spray with natural seawater from Cancale Bay in Brittany, France, for nasal cleansing and moisturizing. Suitable for infants, children, adults, and during pregnancy. CE-marked.

9Well by Orion Pharma
CategoryOTC sub-brand / e-commerce
Description

E-commerce platform offering curated self-care products including dietary supplements and skincare, rooted in Nordic values, providing advice and knowledge for everyday wellness.

10ODM-212
CategoryPrescription drug (oncology)
Description

Prescription oncology drug candidate: a potential best-in-class TEAD inhibitor molecule for treatment of advanced solid tumors including malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Currently in Phase 1b/2 clinical trials (TEADCO study).

11Prescription pharmaceuticals (pain and oncology focus)
CategoryPrescription medications
Description

Prescription drug portfolio covering pain and oncology as core focus areas, along with products for asthma/COPD, allergic rhinitis, neurology (epilepsy, schizophrenia, bipolar disorder), psychiatry, gastroenterology (ulcerative colitis), and prostate cancer. Includes generic drugs and biosimilars.

12Veterinary pharmaceuticals
CategoryAnimal health products
Description

Animal health medications developed and manufactured by Orion, contributing to the wellbeing of animals and pet owners.

13Active pharmaceutical ingredients (APIs)
CategoryB2B/pharmaceutical ingredients
Description

B2B offering: active pharmaceutical ingredients manufactured and supplied to other pharmaceutical companies globally.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Leading Global Research Institutes
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Orion collaborates closely with leading global research institutes for drug discovery and development, particularly in oncology and pain therapeutic areas.

orionpharma.se
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Orion partners with other pharmaceutical companies for co-development and commercialization of pharmaceutical products and therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered European pharma combining generics, specialty pharmaceuticals, and consumer health/OTC products. Highly comparable mix of branded and generic/OTC across European markets.

TypeDirect peer
Description

Swiss pharmaceutical and consumer health company combining pharmacy distribution with branded OTC and prescription products — overlaps with Orion's Nordic pharmacy-channel-driven OTC franchise model.

TypeBroad incumbent
Description

Large global OTC-focused pharmaceutical company with consumer self-care portfolio covering eye care, nasal, pain relief, and ear care categories — directly comparable OTC product categories to Orion's Scandinavian OTC range (Bevita Eye, Stérimar, Pronaxen, Revaxör).

TypeDirect peer
Description

Spanish specialty pharmaceutical company combining prescription dermatology products with OTC/self-care offerings across European markets — comparable European mid-cap pharma with similar Rx + OTC portfolio structure.

TypeDirect peer
Description

Privately-held German specialty pharmaceutical company focused on pain management — directly overlaps with Orion's stated pain therapy R&D focus area and has similar European mid-cap pharma profile.

TypeBroad incumbent
Description

Global pharmaceutical company with leading generics and biosimilars franchise plus branded specialty products — directly comparable to Orion's generic/biosimilar revenue stream and broader diversified pharma model.

TypeDirect peer
Description

Spanish pharmaceutical and OTC consumer health company with a similar mix of branded prescription products and consumer self-care lines across European and Latin American markets.

8H. Lundbeck
TypeDirect peer
Description

Danish specialty pharmaceutical company of similar mid-cap size focused on central nervous system disorders; co-founding partner with Orion in the Apheris ADMET Network. Closely comparable European mid-cap pharma with branded prescription drug focus.

TypeDirect peer
Description

Italian mid-cap pharmaceutical company with a comparable diversified portfolio spanning specialty prescription pharmaceuticals, OTC/self-care products, and rare diseases — the closest structural analog to Orion's prescription-plus-OTC dual model.

TypeDirect peer
Description

French specialty pharmaceutical company with growing oncology and pain/neuroscience focus. Comparable European mid-cap pharma with branded specialty prescription drug model and similar therapeutic area overlap with Orion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orion Pharma

Pharmaceutical Manufacturingorionpharma.se

Orion Corporation is a Finnish pharmaceutical company (founded 1917, Nasdaq Helsinki: ORNBV) developing, manufacturing and marketing prescription drugs focused on oncology and pain, generics and biosimilars, OTC self-care products, veterinary medicines, and APIs, serving patients, healthcare professionals and consumers across over 100 countries.

What Orion Pharma does

Orion Pharma is the consumer-facing brand of Orion Corporation, a Finnish pharmaceutical company founded in 1917 by three pharmacists and now publicly listed on Nasdaq Helsinki under ticker ORNBV. Orion Corporation, headquartered in Espoo, Finland, develops, manufactures and markets human and veterinary medicines, active pharmaceutical ingredients, generics and biosimilars, and a Scandinavian-focused portfolio of OTC medical devices and self-care products sold under brands including AcidDuo, Bevita Eye, Melatonin Orion Pharma, Oriptan, Pronaxen, Pyrvin, Revaxör and Stérimar. The company employs more than 3,500 people across 30+ countries and distributes its products in over 100 countries.

Core R&D is concentrated in two therapeutic areas: oncology and pain. The lead pipeline asset is ODM-212, a proprietary TEAD inhibitor in the Phase 1b/2 TEADCO clinical trial evaluating combination regimens in malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Beyond oncology and pain, Orion's prescription portfolio spans respiratory (asthma/COPD, allergic rhinitis), neurology (epilepsy, neuropathic pain), psychiatry (schizophrenia, bipolar disorder), gastroenterology (ulcerative colitis), and urology (prostate cancer). The self-care and veterinary businesses extend the company's reach into consumer pharmacy shelves and animal health respectively.

Orion generates revenue through one-time sales across prescription pharmaceuticals, OTC/self-care products, veterinary medicines, generics/biosimilars, and B2B API supply. Commercial reach is executed via field sales representatives engaging healthcare professionals, distributor networks for global Rx distribution, retail and online pharmacy chains (Apotea, Apoteket.se, Apotek Hjärtat, Kronans Apotek, DOZ Apotek, MEDS) for OTC products in Scandinavia, and the Well by Orion Pharma e-commerce storefront for direct-to-consumer self-care. The company is also a founding member of the Apheris ADMET Network, a federated AI initiative for collaborative drug-discovery model training alongside Lundbeck, Recursion and Servier.

Orion Pharma firmographics

Firmographics
Name
Orion Pharma
Legal name
Orion Corporation
Website
https://orionpharma.se
Company type
Public
Founded year
1917
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Orion Corporation is a Finnish pharmaceutical company (founded 1917, Nasdaq Helsinki: ORNBV) developing, manufacturing and marketing prescription drugs focused on oncology and pain, generics and biosimilars, OTC self-care products, veterinary medicines, and APIs, serving patients, healthcare professionals and consumers across over 100 countries.
Ownership category
akta.pro rank

Orion Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAMAG
Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAMAIAJ
Animal Health OTC Retail (Parasite Control, Basic Care)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)
SECONDARYHLAMAIAD
Compounding Pharmacies (Veterinary)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Distribution & Retail (Wholesalers, Pharmacies)

Keywords

  • Prescription pharmaceuticals
  • Oncology drug development
  • Pain management medicines
  • OTC self-care products
  • Active pharmaceutical ingredients

Where Orion Pharma is headquartered

Location

Headquarters

HQ city
Danderyd
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Orion Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Prescription Pharmaceuticals: Orion develops, manufactures and markets prescription medicines covering multiple therapy areas including oncology, pain, respiratory (asthma/COPD), neurology (epilepsy, schizophrenia, bipolar disorder), and gastroenterology (ulcerative colitis). Products are distributed through pharmacies and healthcare providers globally.
  2. OTC/Egenvård Products: Self-care/OTC products including AcidDuo (heartburn), Bevita Eye (dry eyes), Melatonin Orion Pharma (jet lag), Oriptan (migraine), Pronaxen (pain), Pyrvin (pinworm), Revaxör (ear wax), and Stérimar (nasal spray). Sold through pharmacies and online pharmacy retailers across Scandinavia.
  3. Veterinary Medicines: Orion develops and manufactures veterinary pharmaceutical products for animal health.
  4. Generic and Biosimilar Drugs: Cost-saving generic and biosimilar pharmaceuticals complementing innovative originator products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Orion Pharma product offering

Product offering

Core offering

Orion Pharma develops, manufactures, and markets pharmaceutical products for humans and animals, with research and development focused on oncology and pain. The company offers a diversified portfolio including prescription drugs, generic and biosimilar medicines, OTC/self-care products (acid reflux, dry eyes, migraine, pain, jet lag, ear/nasal care), veterinary medicines, and active pharmaceutical ingredients supplied to other pharmaceutical companies. Products are available in over 100 countries globally, with OTC brands distributed through pharmacy chains across Scandinavia.

Product overview

Orion Pharma is a Finnish pharmaceutical company operating globally with products in over 100 countries. The company offers a diversified portfolio consisting of prescription medications (with focus on pain and oncology), generic drugs and biosimilars, active pharmaceutical ingredients, veterinary pharmaceuticals, and consumer self-care products. The self-care portfolio includes OTC medical devices and medications sold through pharmacies and online pharmacies across Scandinavia, comprising AcidDuo (heartburn relief), Bevita Eye (dry eye treatment), Melatonin Orion Pharma (jet lag relief), Oriptan (migraine treatment), Pronaxen (pain relief), Pyrvin (pinworm treatment), Revaxör (ear care), and Stérimar (nasal spray with natural seawater), all available under the Orion Pharma brand. The company also operates Well by Orion Pharma as an e-commerce platform for wellness products. Orion's prescription drug development focuses primarily on pain and oncology therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • AcidDuo OTC medical device: chewable tablets that form a protective barrier against stomach acid to relieve heartburn and acid reflux. Sold to consumers through pharmacies across Scandinavia.
  • Bevita Eye OTC medical device: eye drops and ointment for dry eye symptoms, containing hyaluronic acid and vitamin A to moisturize and protect the eye surface. CE-marked, sold through pharmacies.
  • Melatonin Orion Pharma 3 mg and 5 mg OTC medication: melatonin tablets for short-term treatment of jet lag in adults, helping reset the body's internal clock after crossing time zones.
  • Oriptan (sumatriptan) OTC medication: 50 mg sumatriptan tablets for acute migraine attacks with or without aura. Recept-free (non-prescription) OTC format.
  • Pronaxen (naproxen) OTC medication: naproxen tablets providing pain relief, fever reduction, and anti-inflammatory action for adults and adolescents from 12 years for mild to moderate acute pain including menstrual cramps, headache, toothache, muscle and joint pain.
  • Pyrvin (pyrvinium embonate) OTC medication: film-coated tablets for treatment of threadworm (pinworm) in children and adults, administered as a single dose repeated after two weeks.
  • Revaxör OTC medical device: earwax-removing spray and drops plus caring oil for earwax and earwax plug removal. CE-marked, sold through pharmacies.
  • Stérimar OTC medical device: nasal spray with natural seawater from Cancale Bay in Brittany, France, for nasal cleansing and moisturizing. Suitable for infants, children, adults, and during pregnancy. CE-marked.
  • Well by Orion Pharma E-commerce platform offering curated self-care products including dietary supplements and skincare, rooted in Nordic values, providing advice and knowledge for everyday wellness.
  • ODM-212 Prescription oncology drug candidate: a potential best-in-class TEAD inhibitor molecule for treatment of advanced solid tumors including malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. Currently in Phase 1b/2 clinical trials (TEADCO study).
  • Prescription pharmaceuticals (pain and oncology focus) Prescription drug portfolio covering pain and oncology as core focus areas, along with products for asthma/COPD, allergic rhinitis, neurology (epilepsy, schizophrenia, bipolar disorder), psychiatry, gastroenterology (ulcerative colitis), and prostate cancer. Includes generic drugs and biosimilars.
  • Veterinary pharmaceuticals Animal health medications developed and manufactured by Orion, contributing to the wellbeing of animals and pet owners.
  • Active pharmaceutical ingredients (APIs) B2B offering: active pharmaceutical ingredients manufactured and supplied to other pharmaceutical companies globally.

Quantifiable outcome

  • Products available in over 100 countries
  • +1 more outcomes

Companies that use Orion Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Orion Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Orion Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Leading Global Research InstitutescoreStrategic or Co-development PartnerOrion collaborates closely with leading global research institutes for drug discovery and development, particularly in oncology and pain therapeutic areas.
  • Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerOrion partners with other pharmaceutical companies for co-development and commercialization of pharmaceutical products and therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Orion Pharma competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: German-headquartered European pharma combining generics, specialty pharmaceuticals, and consumer health/OTC products. Highly comparable mix of branded and generic/OTC across European markets.
  • Galenica: Swiss pharmaceutical and consumer health company combining pharmacy distribution with branded OTC and prescription products — overlaps with Orion's Nordic pharmacy-channel-driven OTC franchise model.
  • Almirall: Spanish specialty pharmaceutical company combining prescription dermatology products with OTC/self-care offerings across European markets — comparable European mid-cap pharma with similar Rx + OTC portfolio structure.
  • Grünenthal: Privately-held German specialty pharmaceutical company focused on pain management — directly overlaps with Orion's stated pain therapy R&D focus area and has similar European mid-cap pharma profile.
  • Faes Farma: Spanish pharmaceutical and OTC consumer health company with a similar mix of branded prescription products and consumer self-care lines across European and Latin American markets.
  • H. Lundbeck: Danish specialty pharmaceutical company of similar mid-cap size focused on central nervous system disorders; co-founding partner with Orion in the Apheris ADMET Network. Closely comparable European mid-cap pharma with branded prescription drug focus.
  • Recordati: Italian mid-cap pharmaceutical company with a comparable diversified portfolio spanning specialty prescription pharmaceuticals, OTC/self-care products, and rare diseases — the closest structural analog to Orion's prescription-plus-OTC dual model.
  • Ipsen: French specialty pharmaceutical company with growing oncology and pain/neuroscience focus. Comparable European mid-cap pharma with branded specialty prescription drug model and similar therapeutic area overlap with Orion.

Broad incumbents

  • Perrigo: Large global OTC-focused pharmaceutical company with consumer self-care portfolio covering eye care, nasal, pain relief, and ear care categories — directly comparable OTC product categories to Orion's Scandinavian OTC range (Bevita Eye, Stérimar, Pronaxen, Revaxör).
  • Viatris: Global pharmaceutical company with leading generics and biosimilars franchise plus branded specialty products — directly comparable to Orion's generic/biosimilar revenue stream and broader diversified pharma model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Orion Pharma social profiles

Digital presence

Orion Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orion Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Orion Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Orion Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orion Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orion Pharma

What does Orion Pharma do?

Orion Pharma develops, manufactures, and markets pharmaceutical products for humans and animals, with research and development focused on oncology and pain. The company offers a diversified portfolio including prescription drugs, generic and biosimilar medicines, OTC/self-care products (acid reflux, dry eyes, migraine, pain, jet lag, ear/nasal care), veterinary medicines, and active pharmaceutical ingredients supplied to other pharmaceutical companies. Products are available in over 100 countries globally, with OTC brands distributed through pharmacy chains across Scandinavia.

Is Orion Pharma a public or private company?

Orion Pharma is a public company. It is classified as public and is currently operating.

When was Orion Pharma founded?

Orion Pharma was founded in 1917. It employs 1,001 to 5,000 people.

Where is Orion Pharma based?

Orion Pharma is headquartered in Danderyd, Sweden, in the Europe region.

How does Orion Pharma make money?

Four revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are OTC/Egenvård Products, veterinary Medicines and generic and Biosimilar Drugs.

Who are Orion Pharma's main competitors?

Direct peers on record are Stada Arzneimittel, Galenica, Almirall, Grünenthal, Faes Farma, H. Lundbeck, Recordati and Ipsen. Broad incumbents are Perrigo and Viatris.

Does Orion Pharma have an API?

No public API is recorded for Orion Pharma.

What industry is Orion Pharma in?

Orion Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics), with a secondary code of CRADAMAC, OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireOrion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European marketOrion Pharma and Shilpa Biologicals Private Limited (a subsidiary of Shilpa Medicare Limited) have entered into an agreement to commercialize an intravenous nivolumab biosimilar for the European market. Under the terms, Orion will gain exclusive rights to distribute, market, and sell the biosimilar in Europe, while Shilpa will supply the product and receive development and regulatory milestone payments. The partnership expands Orion's hospital segment operations in Continental Europe and moves Shilpa further into the immuno-oncology space.MarketScreenerOrion reports positive Phase 1 cancer dataOrion Pharma reported positive Phase 1 data for ODM-212, showing early signs of clinical activity in mesothelioma and EHE. The overall response rate was 15.6%, with mesothelioma patients responding at 27.8%, and the treatment was well tolerated with no dose-limiting toxicities.GlobeNewswireOrion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä kasvaimiaOrion Pharma has initiated the TEADCO Phase 1b/2 clinical trial evaluating ODM-212, a potential best-in-class TEAD inhibitor molecule, in combination with established treatments for patients with advanced malignant pleural mesothelioma, KRAS G12C-mutant non-small cell lung cancer, and pancreatic cancer. The multi-center study will assess efficacy, safety, dosing, and tolerability across three cohorts, with the first cohort evaluating ODM-212 alongside ipilimumab and nivolumab in first-line treatment for malignant pleural mesothelioma. This represents another milestone in the clinical development of ODM-212, which aims to address treatment resistance and provide antitumor effects across multiple cancer indications.openPR.comEndocrine Therapy Drugs (ETDs) Market Is Booming Worldwide 2026-2033 | Novo Nordisk A/S, AstraZeneca, Orion Pharma ABThe global Endocrine Therapy Drugs (ETDs) market is experiencing significant growth from 2026 to 2033, driven by rapid innovation, rising investments, and regional shifts. Major pharmaceutical companies such as Novo Nordisk A/S, AstraZeneca, and Orion Pharma AB are active participants in this expanding market.PR NewswireGlobal $8.1B Parkinson's Disease Drugs Market Outlook to 2027 - Impact of COVID-19 and Profiles of Key Players Including AbbVie, Boehringer Ingelheim, GSK, Merck & Co, Mylan, Orion Pharma, and PfizerResearchAndMarkets has published a report projecting the global Parkinson's disease drugs market to grow from $5.1 billion in 2020 to $8.1 billion by 2027, with a CAGR of 6.9%. The analysis highlights significant regional growth, particularly in China which is forecast to reach $1.8 billion by 2027, while identifying key industry players such as AbbVie, Pfizer, and Merck & Co.GlobeNewswireOrion Pharma taking actions to improve operational efficiencyOrion Pharma is taking actions to improve operational efficiency, including a proposed reduction of about 70 personnel in its Finnish domestic marketing and sales organization. The company aims to raise operating profit to 20% of net sales, up from 13.7% in 2002, and has also discontinued clinical studies with deramciclane due to insufficient efficacy.GlobeNewswireORION PHARMA AND PHARMACIA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE A NEW ANXIETY MEDICATIONOrion Corporation and Pharmacia announced a collaboration to develop and commercialize deramciclane, an investigational 5-HT2 receptor antagonist for generalized anxiety disorder, in the U.S. The companies will jointly fund and conduct Phase 3 trials, with Pharmacia managing them and marketing the product upon approval. Orion holds an option to co-promote, and Pharmacia gets rights to develop and market outside the U.S. and Europe.GlobeNewswireOrion Pharma's heart failure drug Simdax to be approved in eight european countriesOrion Pharma received favourable mutual recognition decisions for its heart failure drug Simdax in eight European countries, with marketing authorisations expected in coming months. The drug, indicated for acute heart failure, is marketed by Orion in Finland, Norway, and Iceland, and by Abbott in Italy, Spain, Greece, Luxembourg, and Portugal. Orion plans to submit applications for additional approvals in South America, Asia, and non-EU Europe in 2001.